Contact: William Davis
University of North Carolina Health Care
Caption: Using data from health plan claims for the anti-cancer drug imatinib filed between 2002 to 2011, Stacie B. Dusetzina, Ph.D., research professor at the UNC School of Medicine and Gillings School of Global Public Health and member of the UNC Lineberger Comprehensive Cancer Center, found that patients with higher co-payments were 70 percent more likely to stop taking their cancer treatment and 42 percent more likely to skip doses.
Credit: UNC Lineberger Comprehensive Cancer Center
Usage Restrictions: None
Related news release: Out-of-pocket costs play major role in treatment adherence for cancer patients